FDA approves GSK’s anemia drug with safety warning – after knocking back similar drugs – Endpoints News
With Novo Nordisk’s obesity treatment Wegovy fully back in stock in December, sales are starting to skyrocket, the Danish pharmacy reported during its annual earnings call on Wednesday. The total number of scripts of the glucagon-like peptide 1 (GLP-1) Wegovy topped 37,000 weekly in mid-January, a hockey stick increase from the end of the year below 15,000 per week.
The new prescriptions come on top of overall momentum in sales of Novo’s obesity drugs in 2022, although the then-supply-constrained Wegovy was only part of that. Sibling obesity with Saxenda accounted for DKK 10.7 billion (USD 1.58 billion) of the total DKK 16.9 billion (USD 2.49 billion), or approximately 63%, in Novo Nordisk̵[ads1]7;s reported obesity segment sales.
